RNA Based COVID-19 Vaccine Candidates in Clinical Phase
The number of cases and disease-dependent deaths continue to increase worldwide due to the COVID-19 infection accepted as a global pandemic by the World Health Organization on March 11, 2020. Therefore, the antivirals used in treatment and vaccines that are the most effective weapons for protection remain the most popular topic on the agenda. There are a few conditions that might have an impact on the course of the pandemic, including the mutation of the virus and losing its ability to cause disease, generating herd immunity by reaching a critical rate of immunized people in the community due to the disease, and ensuring herd immunity through effective vaccination. Vaccine trials, which have started owing to the severity and urgency of the situation we are in, continue highly rapidly and effectively. According to the March 2, 2021 data of WHO, there are 258 vaccine trials, 76 of which are at the clinical phase, and 9 of the vaccine trials that are at the clinical phase are RNA-based vaccines. In our study, it was aimed to investigate RNA-based COVID-19 vaccine candidates and review their current data..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
---|---|
Enthalten in: |
Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi - 26(2021), 2, Seite 227-231 |
Sprache: |
Englisch ; Türkisch |
---|
Beteiligte Personen: |
Leyla İpek Rudvan Al [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
Covid-19 |
---|
doi: |
10.5578/flora.20219802 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ008405751 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ008405751 | ||
003 | DE-627 | ||
005 | 20230310182700.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.5578/flora.20219802 |2 doi | |
035 | |a (DE-627)DOAJ008405751 | ||
035 | |a (DE-599)DOAJ939cb4bd83d34f11a227fda2ac744fae | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng |a tur | ||
050 | 0 | |a RC109-216 | |
050 | 0 | |a QR1-502 | |
100 | 0 | |a Leyla İpek Rudvan Al |e verfasserin |4 aut | |
245 | 1 | 0 | |a RNA Based COVID-19 Vaccine Candidates in Clinical Phase |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a The number of cases and disease-dependent deaths continue to increase worldwide due to the COVID-19 infection accepted as a global pandemic by the World Health Organization on March 11, 2020. Therefore, the antivirals used in treatment and vaccines that are the most effective weapons for protection remain the most popular topic on the agenda. There are a few conditions that might have an impact on the course of the pandemic, including the mutation of the virus and losing its ability to cause disease, generating herd immunity by reaching a critical rate of immunized people in the community due to the disease, and ensuring herd immunity through effective vaccination. Vaccine trials, which have started owing to the severity and urgency of the situation we are in, continue highly rapidly and effectively. According to the March 2, 2021 data of WHO, there are 258 vaccine trials, 76 of which are at the clinical phase, and 9 of the vaccine trials that are at the clinical phase are RNA-based vaccines. In our study, it was aimed to investigate RNA-based COVID-19 vaccine candidates and review their current data. | ||
650 | 4 | |a rna based vaccines | |
650 | 4 | |a covid-19 | |
653 | 0 | |a Infectious and parasitic diseases | |
653 | 0 | |a Microbiology | |
700 | 0 | |a Meliha Çağla Sönmezer |e verfasserin |4 aut | |
700 | 0 | |a Serhat Ünal |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi |d Bilimsel Tip Yayinevi, 2018 |g 26(2021), 2, Seite 227-231 |w (DE-627)DOAJ000080411 |x 1300932X |7 nnns |
773 | 1 | 8 | |g volume:26 |g year:2021 |g number:2 |g pages:227-231 |
856 | 4 | 0 | |u https://doi.org/10.5578/flora.20219802 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/939cb4bd83d34f11a227fda2ac744fae |z kostenfrei |
856 | 4 | 0 | |u http://floradergisi.org/managete/fu_folder/2021-02/227-231%20Leyla%20ipek%20Rudvan%20Al.pdf |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1300-932X |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1300-932X |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
951 | |a AR | ||
952 | |d 26 |j 2021 |e 2 |h 227-231 |